abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Disease Activity and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis and Sjögren

Author

Rheumatol Int. 2020 May 24. doi: 10.1007/s00296-020-04602-8. Online ahead of print.

Leslie R Harrold 1 2, Ying Shan 3, Sabrina Rebello 3, Neil Kramer 4, Sean E Connolly 5, Evo Alemao 5, Sheila Kelly 5, Joel M Kremer 6, Elliot D Rosenstein 4

Author Information

1 Corrona, LLC, 1440 Main Street, Suite 310, Waltham, MA, 02451, USA. lharrold@corrona.org.

2 University of Massachusetts Medical School, Worcester, MA, USA. lharrold@corrona.org.

3 Corrona, LLC, 1440 Main Street, Suite 310, Waltham, MA, 02451, USA.

4 Institute for Rheumatic & Autoimmune Diseases, Overlook Medical Center, Summit, NJ, USA.

5 Bristol Myers Squibb, Princeton, NJ, USA.

6 Albany Medical College and the Center for Rheumatology, Albany, NY, USA.

Abstract

The objective of this study was to compare rheumatoid arthritis (RA) disease activity and patient-reported outcomes (PROs) in a national sample of patients with RA with/without Sjögren's syndrome (SS). Adults with RA from a large observational US registry (Corrona RA) with known SS status between 22 April 2010 and 31 July 2018 and a visit 12 (± 3) months after index date were identified (n = 36,256/52,757). SS status: determined from a yes/no variable reported at enrolment into the Corrona RA registry and follow-up visits. Index date: date that SS status was recorded (yes/no). Patients received biologic or targeted synthetic disease-modifying antirheumatic drugs as part of standard care. Patients with RA only were followed for ≥ 12 months to confirm the absence of SS. Patients were frequency- and propensity-score matched (PSM) 1:1 and stratified by disease duration and treatment response-associated variables, respectively. Clinical Disease Activity Index (CDAI) and PROs 12 months after index visit were compared in patients with and without SS. Baseline characteristics in 283 pairs of PSM patients were balanced. Mean change in CDAI score was numerically lower in patients with RA and SS than patients with RA only (8.8 vs 9.3). Reductions in PROs of pain, fatigue and stiffness were two- to threefold lower for patients with RA and SS versus RA only. Reductions in RA disease activity and RA-related PROs were lower in patients with RA and SS versus those with RA only. Our data indicate that SS adds to treatment challenges; physicians may wish to consider SS status when managing patients with RA.